Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06073184

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium (WE-FiERCE)

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)

Sponsor: University Health Network, Toronto

Conditions Atypical Hyperplasia Endometrial Cancer

Interventions Mirena Mounjaro

Updated 6 times since 2023 Last updated: Jun 5, 2025 Started: Aug 31, 2025 Primary completion: Feb 28, 2027 Completion: Feb 29, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06073184, this PHASE2 trial focuses on Atypical Hyperplasia and Endometrial Cancer and remains actively recruiting participants. Sponsored by University Health Network, Toronto, it has been updated 6 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Jul 2025 — Present [monthly]

Not Yet Recruiting PHASE2
May 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — May 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Nov 2023 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.